Current Journal of Neurology最新文献_第3页

The effect of atomoxetine on cognitive function in patients with multiple sclerosis 托莫西汀对多发性硬化症患者认知功能的影响

Current Journal of Neurology Pub Date : 2023-10-08 DOI: 10.18502/cjn.v22i3.13792

Ehsan Mohammadian Nejad, Effat Amouzadeh, Davood Kashipazha, Gholamreza Shamsaei, Bahman Cheraghian

{"title":"The effect of atomoxetine on cognitive function in patients with multiple sclerosis","authors":"Ehsan Mohammadian Nejad, Effat Amouzadeh, Davood Kashipazha, Gholamreza Shamsaei, Bahman Cheraghian","doi":"10.18502/cjn.v22i3.13792","DOIUrl":"https://doi.org/10.18502/cjn.v22i3.13792","url":null,"abstract":"Background: Recent research shows that most of the patients with multiple sclerosis (MS) have cognitive-like disorders. Due to the beneficial effects of atomoxetine on improving cognition in limited animal and human surveys, the aim of the present study was to investigate the effect of the atomoxetine on improving cognitive disorders of MS. Methods: This study was a parallel, randomized clinical trial, designed to investigate the effect of atomoxetine drug on the improvement of cognitive impairment (CI) in MS, from April 2021 to March 2022. According to the inclusion and exclusion criteria, a total of 52 participants were involved in the study and then randomly divided in two groups of 26. Experimental group was treated with atomoxetine and the control group was treated with placebo. The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) test was performed for assessment at the beginning and after 3 months. The California Verbal Learning Test (CVLT), the CVLT-delay, the Brief Visuospatial Memory Test-Revised (BVMT-R), and the Symbol Digit Modalities Test (SDMT) were used to evaluate the CI and changes following medication. Finally, data were analyzed by SPSS software at significance level of 0.05. Results: The mean age of patients in the experimental group was 37.7 ± 8.5 and in the placebo group was 37.8 ± 7.6 (P = 0.32). The results showed significant changes in cognitive levels before and after the use of atomoxetine and also in comparison to the placebo group (P < 0.05). Conclusion: This study showed that atomoxetine improved the cognitive domains after administration compared to placebo.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognosis and outcome in patients with chronic inflammatory demyelinating polyradiculoneuropathy in a tertiary center in Oman 阿曼三级中心慢性炎症性脱髓鞘性多根神经病变患者的预后和结局

Current Journal of Neurology Pub Date : 2023-10-08 DOI: 10.18502/cjn.v22i3.13791

Mai Elrayes, Abdullah AlSalti

{"title":"Prognosis and outcome in patients with chronic inflammatory demyelinating polyradiculoneuropathy in a tertiary center in Oman","authors":"Mai Elrayes, Abdullah AlSalti","doi":"10.18502/cjn.v22i3.13791","DOIUrl":"https://doi.org/10.18502/cjn.v22i3.13791","url":null,"abstract":"Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated condition with variable clinical characteristics and different treatment modalities. We aim to present different clinical and demographic features of all patients with CIDP presented to the neuromuscular clinic within four years and their follow-up results. Methods: A retrospective study from a hospital database of 23 patients met the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIPD. Complete demographic and clinical data were collected. Progress and outcome were assessed using two clinical score systems at regular intervals at 6, 12, and 18 months. Results: Mean age of patients was 43.4 ± 20.9 years (male-to-female ratio was 1.6:1). Age of onset was 39.7 ± 18.0 years. At the presentation, the Medical Research Council sum score (MRCss) was 50 (39.7-51.3), and the modified Rankin Scale (mRS) was 3 (2.2-3.4). There was a significant improvement in MRCss during four periods (P < 0.001). Multiple comparisons revealed a significant difference in MRCss between the baseline and 12 and 18 months but no significant change between the baseline and 6 months. Likewise, mRS showed a significant improvement between the baseline and 18 months (no significant change between the baseline and 6 months or 12 months). Conclusion: The clinical characteristics of CIDP in our cohort were similar to other reported studies, and most of the studied patients had good outcomes. Our results could be utilized as baseline data for a better understanding of the characteristics of CIDP in Oman and, consequently, for better management of the disease.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus, not receiving any immunosuppressant medication 系统性红斑狼疮患者的进行性多灶性白质脑病，未接受任何免疫抑制药物治疗

Current Journal of Neurology Pub Date : 2023-08-08 DOI: 10.18502/cjn.v22i2.13341

Bardiya Ghaderi, Alaleh Vaghefifar, Farideh Darabi, Hajir Sikaroodi

引用次数: 0

Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran 伊朗Chaharmahal和Bakhtiari省多发性硬化症流行病学参数

Current Journal of Neurology Pub Date : 2023-08-08 DOI: 10.18502/cjn.v22i2.13337

Mohammad Amin Omrani, Asghar Bayati, Mohammad Ali Sahraian, Sharareh Eskandarieh

{"title":"Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran","authors":"Mohammad Amin Omrani, Asghar Bayati, Mohammad Ali Sahraian, Sharareh Eskandarieh","doi":"10.18502/cjn.v22i2.13337","DOIUrl":"https://doi.org/10.18502/cjn.v22i2.13337","url":null,"abstract":"Background: Multiple sclerosis (MS) is a neurological disease with a high burden and disability. There are reports of various medications’ side effects on patients with MS. The aim of the study is to determine the characteristics and medicine usage distribution among patients with MS in Chaharmahal and Bakhtiari Province in Iran. Methods: This registry-based cross-sectional study was performed among MS cases in Chaharmahal and Bakhtiari Province. The epidemiological data were collected from the nationwide MS registry of Iran (NMSRI) from 2019 to 2022. The information collected included age, sex, family history, type of MS, age at MS onset and diagnosis, MS symptoms, physical condition, and history of medication use. All tests were performed at a significance level of 0.05 using SPSS software. Results: A total of 416 patients included in this study. Among them, 325 individuals (78%) were women with mean ± standard deviation (SD) of age of 37.35 ± 8.51 years. No significant difference was observed between men and women in terms of age, type of MS disease, family history of MS, and physical condition (P > 0.05). The results showed that the Expanded Disability Status Scale (EDSS) score in female patients (1.41) was different from the EDSS score in male patients (1.77) (P < 0.05). Most of the patients often used interferon beta (IFN-β). Conclusion: The results provided new insight into the epidemiology and medicine patterns of patients with MS in Chaharmahal and Bakhtiari Province. The epidemiological situation of MS in this province is similar to other parts of Iran. Planning according to national programs is suggested for the management and control of MS.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135795068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models. 多发性硬化症诊断延迟月数的相关因素：计数回归模型的比较

IF 0.7

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13330

Abolfazl Hosseinnataj, Roya Nikbakht, Seyed Nouraddin Mousavinasab, Sharareh Eskandarieh, Mohammad Ali Sahraian, Seyed Mohammad Baghbanian

{"title":"Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models.","authors":"Abolfazl Hosseinnataj, Roya Nikbakht, Seyed Nouraddin Mousavinasab, Sharareh Eskandarieh, Mohammad Ali Sahraian, Seyed Mohammad Baghbanian","doi":"10.18502/cjn.v22i2.13330","DOIUrl":"10.18502/cjn.v22i2.13330","url":null,"abstract":"Background: It may take a long time to diagnose multiple sclerosis (MS) since the emergence of primary symptoms. This study aimed to use count regression models to compare their fit and to identify factors affecting delay in the diagnosis of MS. Methods: Data were collected from the Nationwide MS Registry of Iran (NMSRI) for Mazandaran Province, Iran, using census sampling until April 2022. The four models of Poisson regression, negative binomial (NB) regression, zero-inflated Poisson (ZIP) regression, and zero-inflated negative binomial (ZINB) regression were used in this study. Results: In this study on 2894 patients, 74.0% were women, and 8.5% had a family history of MS. The mean ± standard deviation (SD) of the patients' age was 34.96 ± 9.41 years, and the mean delay in diagnosis was 12.32 ± 33.26 months, with a median of 0 (Q1-Q3: 0-9). The NB regression model showed the best performance, and factors, including a history of hospitalization and the year of symptom onset, had significant effects on a delayed diagnosis. Besides, the Expanded Disability Status Scale (EDSS) score was significantly different before and after 2017; it was also associated with sex, type of MS, and history of hospitalization. Conclusion: The mean diagnostic delay and the mean age of MS diagnosis are critical in Mazandaran Province. Patients with MS develop the disease at an early age and are diagnosed with a long delay. The time of symptom onset is a significant factor in the diagnosis of MS, and in recent years, there have been improvements in the diagnostic process.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46736067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review. 芬戈莫德交替给药治疗复发缓解型多发性硬化症：一项系统综述

IF 0.7

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13339

Fereshteh Ghadiri, Omid Mirmosayyeb, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Mahsa Ghajarzadeh

{"title":"Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review.","authors":"Fereshteh Ghadiri, Omid Mirmosayyeb, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Mahsa Ghajarzadeh","doi":"10.18502/cjn.v22i2.13339","DOIUrl":"10.18502/cjn.v22i2.13339","url":null,"abstract":"Background: Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficacy measures of this method. Methods: PubMed (Medline®), Web of Science, Embase, Scopus, and the Cochrane Library databases were searched until April 9, 2021. Clinical studies (other than case reports and case series), in English, were included. Then, publications concerning alternate dose fingolimod (including every other day, every two or three days) were selected. Those studies concerning reduced daily dose (any daily dose less than 0.5 mg/day) were excluded to focus on alternate dosing. Results: Four observational studies were included. Data on Ohtani et al. study were limited. Three other studies were of good quality based on the Newcastle-Ottawa Scale. A total of 296 patients on the standard dose were compared to 276 patients on the alternate dosage. The most common reason for switching to the alternate dose was lymphopenia, followed by elevated liver enzymes. Two studies concluded that the alternate dosing could be a safe, yet effective strategy in patients with intolerable adverse effects of daily dose. However, Zecca et al. warned about the high possibility of disease reactivation. Due to the differences in outcome measures of the studies, meta-analysis was not applicable. Conclusion: This systematic review highlights the ambiguity of evidence on safety and efficacy of alternate dosing of fingolimod, encouraging further research on the subject.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43823245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports. 醋酸格拉替默和干扰素β -1a在多发性硬化症患者中的不良副作用:对病例报告的系统回顾

IF 0.7

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13340

Mohsen Rastkar, Mahsa Ghajarzadeh, Mohammad Ali Sahraian

{"title":"Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.","authors":"Mohsen Rastkar, Mahsa Ghajarzadeh, Mohammad Ali Sahraian","doi":"10.18502/cjn.v22i2.13340","DOIUrl":"10.18502/cjn.v22i2.13340","url":null,"abstract":"Background: Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients. Methods: Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers. The risk of bias was assessed using the Joanna Briggs Institute (JBI) tool. Results: We identified 2103 records from the preliminary search. After deduplication and screening, 172 articles were included in the systematic review. In total, 229 individuals (52 men, 173 women, and 4 unknown) were included in the study. The most common adverse events were cutaneous (32.75%), hepatic (13.54%), allergic (8.3%), and neurological (5.68%) side effects. Furthermore, most reported side effects were related to autoimmune diseases or hypersensitivity reactions. Conclusion: GA and IFN beta-1a are associated with several side effects which may be related to the immunomodulatory function of medication or other injection-related reactions.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45412666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iranian specialists' approach to surgery in patients with multiple sclerosis. 伊朗专家对多发性硬化症患者的手术方法

IF 0.7

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13336

Fereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Hora Heidari, Zohreh Abna, Marzieh Aboutorabi, Iman Adibi, Seyed Mohammad Baghbanian, Sepideh Paybast, Maryam Poursadeghfard, Samaneh Hosseini, Sareh Shahmohammadi, Mehran Ghaffari, Hamidreza Ghalyanchi-Langroodi, Masoud Ghiasian, Hoda Kamali, Ebrahim Kouchaki, Farzad Mahrabi, Ehsan Mohammadianinejad, Mohammad Ali Nahayati, Abdorreza Naser Moghadasi

{"title":"Iranian specialists' approach to surgery in patients with multiple sclerosis.","authors":"Fereshteh Ghadiri, Zahra Ebadi, Elnaz Asadollahzadeh, Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Hora Heidari, Zohreh Abna, Marzieh Aboutorabi, Iman Adibi, Seyed Mohammad Baghbanian, Sepideh Paybast, Maryam Poursadeghfard, Samaneh Hosseini, Sareh Shahmohammadi, Mehran Ghaffari, Hamidreza Ghalyanchi-Langroodi, Masoud Ghiasian, Hoda Kamali, Ebrahim Kouchaki, Farzad Mahrabi, Ehsan Mohammadianinejad, Mohammad Ali Nahayati, Abdorreza Naser Moghadasi","doi":"10.18502/cjn.v22i2.13336","DOIUrl":"10.18502/cjn.v22i2.13336","url":null,"abstract":"Background: Data on perioperative risk stratification in patients with multiple sclerosis (MS) are limited. In this regard, the present study was conducted to investigate Iranian specialists' approach to surgical counseling for patients with MS (PwMS). Methods: 21 MS specialists were asked about 11 case scenarios with different MS disease statuses, disease-modifying therapies (DMTs), and urgency of the operation. The reasons for refusing surgery or factors that have to be considered before surgery were studied. Results: Overall, Fleiss Kappa was estimated to be 0.091 [95% confidence interval (CI): 0.090-0.093, P < 0.001] indicating a very poor level of agreement among responders. Conclusion: PwMS face surgery for various reasons. Risk assessment of surgery, the effect of various drugs such as anesthetics and DMT on patients, as well as many other aspects of MS are issues challenging the practitioners. Clarifying the various dimensions of these issues requires further research.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44709150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of dietary patterns with migraine: A matched case-control study. 饮食模式与偏头痛的相关性：一项匹配的病例对照研究

IF 0.5

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13333

Fahimeh Martami, Mansoureh Togha, Mostafa Qorbani, Donya Shahamati, Zhaleh Salami, Sakineh Shab-Bidar

{"title":"Association of dietary patterns with migraine: A matched case-control study.","authors":"Fahimeh Martami, Mansoureh Togha, Mostafa Qorbani, Donya Shahamati, Zhaleh Salami, Sakineh Shab-Bidar","doi":"10.18502/cjn.v22i2.13333","DOIUrl":"10.18502/cjn.v22i2.13333","url":null,"abstract":"Background: Little is known about the association between dietary patterns and odds of migraine. We aimed to investigate the association between posteriori dietary patterns and migraine odds and migraine-related outcomes using principal component analysis (PCA). Methods: A total of 500 participants enrolled in this age- and sex-matched case-control study. Subjects in the case group were migraine patients who were diagnosed by a neurologist (n = 250) and subjects in the control group were healthy individuals (n = 250). Dietary intake was assessed using a 168-item semi-quantitative Food Frequency Questionnaire (FFQ). Extraction of dietary patterns was performed via PCA. Information on the wide range of covariates and migraine-related outcomes were collected. Results: The 2 major dietary patterns of the \"Western diet\" and \"prudent diet\" were extracted using PCA. Those who were in the highest quartile of the prudent diet had the lowest odds of migraine in the fully adjusted model [odds ratio (OR) = 0.10; 95% confidence interval (CI): 0.04-0.21]. Additionally, higher adherence to the Western diet was positively associated with migraine odds (P ˂ 0.001) and this association remained significant and even increased after adjusting a wide range of confounders. Among migraine sufferers, those who had the highest score on the Western diet, had significantly higher attack frequency compared to the patients in the first quartile (15.4 ± 8.9 vs. 12.3 ± 8.6; P = 0.004). Conclusion: The finding of a significant association between the 2 extracted dietary patterns and migraine odds highlights the possible role of diet in both the prevention and stimulation of migraine.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45904394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study. 水烟、吸烟、吸毒和饮酒与原发性进行性多发性硬化症的风险：一项基于人群的病例对照研究

IF 0.5

Current Journal of Neurology Pub Date : 2023-04-04 DOI: 10.18502/cjn.v22i2.13331

Seyyed Hosein Mortazavi, Abdorreza Naser Moghadasi, Amir Almasi-Hashiani, Mohammad Ali Sahraian, Hooman Goudarzi, Sharareh Eskandarieh

{"title":"Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study.","authors":"Seyyed Hosein Mortazavi, Abdorreza Naser Moghadasi, Amir Almasi-Hashiani, Mohammad Ali Sahraian, Hooman Goudarzi, Sharareh Eskandarieh","doi":"10.18502/cjn.v22i2.13331","DOIUrl":"10.18502/cjn.v22i2.13331","url":null,"abstract":"Background: Multiple sclerosis (MS) is a chronic central nervous system disease, and primary progressive multiple sclerosis (PPMS) is one the main types of MS, which has unknown environmental risk factors. The present study was conducted with the aim to identify the association of waterpipe and cigarette smoking, substance abuse, and alcohol consumption with the risk of PPMS development. Methods: A population-based, case-control study was conducted in Tehran, Iran, on 146 PPMS cases and 294 controls. PPMS cases were diagnosed and confirmed by neurologists. Standard random digit dialing was used to select sex-matched healthy control participants from the same source population as the cases. Logistic regression analysis was used to estimate unadjusted and adjusted odds ratios (OR). Results: In total, 440 subjects participated in the study. PPMS was associated with ever smoking cigarettes [OR = 2.48; confidence interval (CI) = 1.44-4.27], and passive smoking (OR = 2.20; CI = 1.34-3.62). However, having ever smoked waterpipe was not significantly associated with PPMS risk (OR = 1.19; CI = 0.62-2.26). Those who had all 3 types of smoking had an accumulative OR that was 10.45 times higher than that in individuals without any type of smoking (OR: 10.45; 95% CI = 3.5-31.2). We did not find any significant association between PPMS risk and substance abuse and alcohol consumption. Conclusion: Cigarette smoking and being exposed to passive smoking are important risk factors for developing PPMS; in addition, the use of 3 types of smoking, showed an OR higher than that in those without any smoking. Considering the global increase in tobacco smoking, this finding emphasizes the importance of interventional programs for the prevention of tobacco smoking.","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48672845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0